ArticleLipids in health and disease2025
Lipemia and its associations with liver disease and dyslipidemia: a cross-sectional study.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLipemia is characterized by a milky appearance of plasma, which can be easily detected using an automated clinical chemistry analyzer. To date, few studies have evaluated the relationship between lipemia values and clinical test data other than lipid parameters. This study aimed to analyze the relationship among lipemia, clinical test data, and associated disorders.
methodsThis cross-sectional study examined 730 specimens from patients with and without lipemia who visited the Niigata University Medical and Dental Hospital in Japan. The participants were divided according to their lipemia index (LIP) into non- (< 1.5 LIP), low- (1.5-4.9 LIP), and high-lipemia (≥ 5.0 LIP) groups. Twenty-seven clinical analytes were analyzed, and their associations with the extent of lipemia were investigated using group comparisons, multinomial logistic regression, and correlation analyses. The prevalence of dyslipidemia and liver disease was also evaluated in the lipemic group.
resultsThe lipemic group exhibited higher total cholesterol and triglyceride levels than the non-lipemia group (P < 0.01). The high-lipemia group demonstrated significantly higher median liver chemistries than the non-lipemia group: aspartate aminotransferase, 27 U/L (interquartile range [IQR], 22-35 U/L) vs. 23 U/L (IQR, 20-28 U/L); gamma-glutamyltransferase, 39 U/L (IQR, 26-79 U/L) vs. 24 U/L (IQR, 16-40 U/L) (P < 0.01). Individuals in the high-lipemia group had a higher complication rate of concomitant dyslipidemia and liver disease.
conclusionLipemia was associated with elevated lipid metabolism-related parameters and liver chemistries. The LIP can be used to evaluate risks associated with liver disease and dyslipidemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.